Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sapanisertib - Takeda Oncology

Drug Profile

Sapanisertib - Takeda Oncology

Alternative Names: CB-228; FTH-003; HY-13328; INK-128; MLN-0128; TAK-228

Latest Information Update: 13 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intellikine
  • Developer Calithera Biosciences; Dana-Farber Cancer Institute; European Network for Translational Research in Ovarian Cancer (EUTROC); M. D. Anderson Cancer Center; National Cancer Institute (USA); Stanford University School of Medicine; Takeda; Takeda Oncology
  • Class Antineoplastics; Benzoxazoles; Pyrazolones; Pyrimidines; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Cancer; Endometrial cancer; Fallopian tube cancer; Glioblastoma; Neuroendocrine tumours; Ovarian cancer; Peritoneal cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Soft tissue sarcoma; Thyroid cancer; Urogenital cancer
  • Phase I/II Liver cancer; Merkel cell carcinoma; Sarcoma
  • Preclinical Leukaemia
  • No development reported Non-small cell lung cancer; Solid tumours
  • Discontinued HER2 negative breast cancer; Multiple myeloma; Prostate cancer; Renal cell carcinoma; Triple negative breast cancer; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 06 Feb 2025 National Cancer Institute plans a phase I/II trial for Liver cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease) in May 2025 (PO) (NCT06811116)
  • 12 Dec 2024 Phase-II clinical trials in Endometrial cancer (Combination therapy, Recurrent, Second-line therapy or greater, Late-stage disease, Inoperable/Unresectable) in USA (PO) (NCT06463028)
  • 09 May 2024 Phase-II clinical trials in Cancer (Late-stage disease, Metastatic disease) in USA (PO) (NCT06385496)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top